Area of research
Hepatology · Epidemiology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Cancer, Lipids, and Metabolism, and Liver Disease and Transplantation.
Breeding from 1891 to 2010 did not increase the content of amylase/trypsin-inhibitors in wheat (Triticum aestivum)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients
High pretreatment static and dynamic alpha‐fetoprotein values predict reduced overall survival in hepatocellular carcinoma
Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma
Sarcopenia as prognostic factor for survival after orthotopic liver transplantation
Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?
Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma
Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma
Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort
Kaposi sarcoma herpesvirus pathogenesis
Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency
Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma
Portal vein infiltration in patients with hepatocellular carcinoma: The relevance of correct classification.
Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment
Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma
Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma
Survival analysis of proposed <scp>BCLC</scp>‐B subgroups in hepatocellular carcinoma patients
Predictive Scores in Primary Biliary Cirrhosis
Trends in Epidemiology, Treatment, and Survival of Hepatocellular Carcinoma Patients Between 1998 and 2009
Dietary Habits and Metabolic Control in Adolescents and Young Adults with Phenylketonuria: Self-Imposed Protein Restriction May Be Harmful
Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation
Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation
Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver
The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib